A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs BIIB 076 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 08 Nov 2019 Planned End Date changed from 14 Feb 2020 to 3 Mar 2020.
- 08 Nov 2019 Planned primary completion date changed from 14 Feb 2020 to 3 Mar 2020.
- 08 Nov 2019 Status changed from recruiting to active, no longer recruiting.